46
Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

Embed Size (px)

Citation preview

Page 1: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

Metabolic Syndrome

Malek M., MDAssociated Professor of Endocrinology and Metabolism

Semnan University of Medical Sciences

Page 2: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences
Page 3: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

METABOLIC SYNDROME

• HISTORY

• DEFINITIONS

• PREVALANCE

• IMPORTANCE OF METABOLIC SYNDROME

• CRITICAL LOOK AT THE METABOLIC SYNDROME

• TREATMENT

Page 4: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

“Metabolic syndrome is a cluster of the most dangerous cardiovascular risk factors namely diabetes, abdominal obesity, high lipid and elevated blood pressure”.

METABOLIC SYNDROME

Page 5: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

Other Names UsedOther Names Used

• Syndrome X• Cardiometabolic Syndrome• Cardiovascular Dysmetabolic Syndrome• Insulin-Resistance Syndrome• Metabolic Syndrome• Reaven’s Syndrome• etc.

Page 6: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

Metabolic Syndrome (History)Metabolic Syndrome (History)

• 1923 - Kylin first to describe the clustering of hypertension, hyperglycemia, hyperuricemia

• 1936 - Himsworth first reported Insulin insensitivity in diabetics

• 1965 - Yalow and Berson developed insulin assay and correlated insulin levels & glucose lowering effects in resistant and non-resistant individuals

Page 7: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

Metabolic Syndrome HistoryMetabolic Syndrome History (cont.)(cont.)

• 1988 - Reaven in his Banting lecture at the ADA meeting coined the term Syndrome X and brought into focus the clustering of features of Metabolic Syndrome

Page 8: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

• World Health Organization (WHO) 1998

• Adult Treatment Panel III, 2001• American Association of Clinical

Endocrinologists (AACE2003)

• International Diabetes Foundation (IDF 2005)

• European Group for the Study of Insulin Resistance, EGIR

• American Heart Association (AHA) and National Heart, Lung and Blood Institute (NHLBI), 2005

Metabolic Syndrome (History)Metabolic Syndrome (History)

Page 9: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

Definitions & Criteria of Diagnosis

Page 10: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

WHO definition of ‘Metabolic Syndrome’

AT LEAST ONE OF:• glucose intolerance• IFG • type 2 diabetes• insulin resistance*

AT LEAST TWO OF:• arterial pressure

140/90 mmHg• plasma triglycerides

1.7 mmol/l or 150 mg/dl and/or HDL cholesterol < 0.9 mmol/l or 35 mg/dl for men; < 1.0 mmol/l or 39 mg/dl for women

• central obesity waist:hip ratio > 0.90 for men,

• > 0.85 for women;• and/or BMI > 30 kg/m2

• microalbuminuria urinary albumin excretion rate 20 g/min or albumin to creatinine ratio 30 mg/g

* Insulin resistance defined under hyperinsulinemic, euglycemic conditions as glucose uptake below the lowest quartile for the background population under investigation

+

World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: Diagnosis and classification of diabetes mellitus. WHO Department of Noncommunicable Disease Surveillance; 1999.

Page 11: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

Draw backs in the WHO Definition

1- BMI is not a reliable measure to obesity

2- Microalbuminuria is very rarely found in

absence of diabetes.

3- Euglyc. clamp is not practically applicable

(clinically or epidem.)

Page 12: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

Risk Factor Criterion

Abdominal ObesityMen Women

Waist Circumference>102 cm (>40 in) >88 cm (>35 in)

Triglycerides 150 mg/dL

HDL-CholesterolMenWomen

<40 mg/dL<50 mg/dL

Blood Pressure 130/85 mm Hg

Fasting Glucose 110 mg/dL

NCEP ATP III. JAMA. 2001;285:2486-2497.

The Metabolic Syndrome (ATP III) & Criteria

Page 13: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

The ATP III Definition 2001( cont. )

Draw back

- absence of ethnic consideration in the cut-off points.

Page 14: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

International Diabetes Federation (IDF) Consensus Definition 2005

Central Obesity

Waist circumference – ethnicity specific*

– for Europids: Male > 94 cm

Female > 80 cm

plus any two of the following:

Raised triglycerides > 150 mg/dL (1.7 mmol/L)

or specific treatment for this lipid abnormality

Reduced HDL cholesterol < 40 mg/dL (1.03 mmol/L) in males

< 50 mg/dL (1.29 mmol/L) in females

or specific treatment for this lipid abnormality

Raised blood pressure Systolic : > 130 mmHg or

Diastolic: > 85 mmHg or

Treatment of previously diagnosed hypertension

Raised fasting plasma glucose

Fasting plasma glucose > 100 mg/dL (5.6 mmol/L) or

Previously diagnosed type 2 diabetes

If above 5.6 mmol/L or 100 mg/dL, OGTT is strongly recommended but is not necessary to define presence of the syndrome.

Page 15: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

Ethnic specific values for waist circumference

Country / Ethnic group Waist circumference

Europids*

In the USA, the ATP III values ( 102 cm male; 88 cm female) are likely to continue to be

used for clinical purposes

Male

Female

94 cm

80 cm

South Asians

Based on a Chinese , Malay and Asian-Indian population

Male

Female

90 cm

80 cm

Chinese Male

Female

90 cm

80 cm

Japanese** Male

Female

90 cm

80 cm

Ethnic South and Central Americans Use South Asian recommendations until more specific data are available

Sub-Saharan Africans Use European data until more specific

data are available EMME ( Arab) populations Use South Asian recommendations

until more specific data are available

Page 16: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

Waist circumference cut-off points for the diagnosis of metabolic syndrome in Iranian adults.

• 91.5cm in men

• 85.5cm in women

Esteghamatit A et al. Diabetes Res Clin Pract. 2008 Oct;82(1):104-7.

Page 17: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

The IDF Definition does not have the final word

1- more research will possibly reveal more accurate

predictive indices.

2- other major risk factors for CVD

( e.g. smoking & LDL cholesterol )

must be taken in consideration

Page 18: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences
Page 19: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences
Page 20: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

Prevalence of the Metabolic Syndrome

Page 21: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

50

40

30

20

10

0

Pre

vale

nce

(%

)

Years of age20-70+ 20-29 30-39 40-49 50-59 60-69 70+

Metabolic syndrome was defined according to NCEP ATP III criteria.Ford ES JAMA 2002;287:356-9

MenWomen

Prevalence of the Metabolic Syndromeaccording to age

Page 22: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

Prevalence of ATP III metabolic syndrome among subjects in the NHANES III survey by

race/ethnicity and sex

Ford, ES. JAMA 2002; 287:356.

Page 23: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

Comparing criteria in defining populations 

• Using data from the National Health and Nutrition Examination Survey 1999-2002 database;

1- IDF criteria: 39 percent • ATP III criteria: 34.5 percent2- the IDF criteria categorized 15 to 20

percent more adults with the metabolic syndrome than the ATP III criteria .

1-Ford, ESDiabetes Care 2005; 28:2745. 2-Adams, RJ. Diabetes Care 2005; 28:2777.

Page 24: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

Why is MetS Important?

Page 25: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

• Causes 2-3 fold increase in cardiovascular risk of mortality.

• Considered as a risk factor for Diabetes mellitus (up to 5% fold increase in risk).

• Even with 2 components- increased mortality from CVD and CHD.

• Risk of stroke increases 3 fold.

• Reduced cardiorespiratory fitness.

• Associated with: Essential hypertension, Polycystic ovarian syndrome, Nonalcoholic fatty liver disease Gallstone disease, Cancer (i.e., breast cancer), Sleep apnea

Why is MetS Important?

Page 26: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences
Page 27: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

Risk of CVD  • Three meta-analyses found that the metabolic

syndrome increases the risk for incident cardiovascular disease (CVD) (RRs ranging from 1.53 to 2.18) and all cause mortality (RRs 1.27 to 1.60)

[1] Ford, ES. Diabetes Care 2005; 28:1769. [2] Galassi, A, Reynolds, K, He, J. Am J Med 2006; 119:812. [3] Gami, AS, Witt, BJ, Howard, DE.J Am Coll Cardiol 2007; 49:403.

Page 28: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

Prediction of cardiovascular disease by metabolic syndrome in individuals aged over 40 yrs according to the ATP III and IDF definition: Tehran Lipid and Glucose Study

• (45%) MS according to the ATP III and• (50%) IDF criteria

• The ATP III and IDF similarly predict CVD • neither of the 2 definitions had this predictive power after adjustment of

their components in addition to the earlier mentioned ones.

• Malek et al.IJEM.2006

Page 29: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

Prevalence of Metabolic Syndrome by the ATPIII, DF, and WHO Definitions and their Association with CHD in

an Elderly Iranian Population

ATPIII and WHO definitions seem to be more pertinent than IDF for screening CHD risk. None of these definitions showed association with CHD when considering their components.

prevalence of MS was 50.8%, 41.8% and 41.9% based on the (ATPIII),(WHO), and (IDF)definitions, respectively

Hadaegh,Ann Acad Med Singapore 2009;38:142-9

Page 30: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

Predictive value for diabetes

• strong predictive value of MetS for diabetes with both the NCEP and the WHO definition.

(1)Edelstein SL, Diabetes 1997;46(4):701–10.(2) Ohlson LO,. Diabetes 1985;34(10):1055–8.(3) Haffner SM.Diabetes Care 1986;9(2):153–61.(4) Kaye SA. J Clin Epidemiol 1991;44(3):329–34.(5) Despre´ s JP. Diabetes 1989;38(3):304–9.

Page 31: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

• Framingham Offspring Study: the NCEP definition showed a 6.9 fold risk

and the WHO definition a 6.1 fold risk for type 2 diabetes

• Insulin Resistance Atherosclerosis Study;• the NCEP, WHO, and IDF definitions of the

MetS had similar predictive values for the incidence of type 2 diabetes, with adjusted odds ratios of 4.1, 3.7, and 3.4, respectively

[1] Wilson PW. Circulation 2005;112(20):3066–72.[2] Hanley AJCirculation 2005;112(24):3713–21.

Predictive value for diabetes

Page 32: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

1- IDF definition is not better in predicting cardiovascular disease than the NCEP definition in the Japanese Diabetes Complication Study

2-IDF definition is not superior to either the NCEP or the WHO definitions in predicting diabetes in the Insulin Resistance and Atherosclerosis Study (IRAS) population.

1- Sone H. Diabetes Care 2006;29(1):145–7.2- Hanley AJ. Circulation 2005;112(24):3713–21.

IDF definition was compared with the NCEP definition:

Page 33: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

Mortality Associated With Metabolic Syndrome

Lakka H-M et al. JAMA. 2002;288:2709-2716.

18

9

6

8

32

0

2

4

6

8

10

12

14

16

18

20

All-cause mortality* CVD mortality* CHD mortality*

Metabolic syndrome

No metabolic syndrome

Mo

rtal

ity

(% o

f p

atie

nts

)

2003 PPS®

*Adjusted for known CHD risk factors.

POWERSEARCH PLUG-IN™ 2.0Copyright © 2001-02 Accent Graphics, Inc.

Slide Source: "R:\NDEI-2\2004 Grant\T108\ARS\T095 ARS Case 2 FINAL-Baton Rouge 12-09-03.ppt" <OPEN>Last Modified: December 9, 2003 2:17:25 PMSlide Number: 19

POWERSEARCH PLUG-IN™ 2.0Copyright © 2001-02 Accent Graphics, Inc.

Slide Source: "R:\NDEI-2\2004 Grant\T108\ARS\T095 ARS Case 2 FINAL-Baton Rouge 12-09-03.ppt" <OPEN>Last Modified: December 9, 2003 2:17:25 PMSlide Number: 19

Page 34: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

Sattar Circulation 2003;108:414-419

Hea

rt D

isea

se3.7 Fold Increase Heart Disease Risk with 4-5 Features of the Metabolic Syndrome

Page 35: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

Sattar Circulation 2003;108:414-419

Dia

bete

s24.5 Fold Increase Risk of New Onset DM with

4-5 Features of the Metabolic Syndrome

Page 36: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

PATHOGENESIS

Page 37: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

GeneralizedMetabolic

Derangement(Insulin Resistance)

Obesity

Physical Inactivity

Adipose TissueDisorders

GeneticInsulin

Resistance

EndocrineDysfunction

Drugs

Genetics &Ethnicity

Race andEthnicity

Risk Factor SpecificMetabolic

Derangement

Ethnic andIndividualVariation

MultipleMetabolic

RiskFactors

Page 38: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

Confusion results from different definitions Why ?

differences in 1- the components of the MTS

2- the cut- off points

This causes difficulties in :

1- identifying the MTS i.e. diagnosing

2- interpretation of its causation

3- comparing its burden in different populations

Page 39: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

A CRITICAL LOOK AT THE METABOLIC SYNDROME 

Lack of clarity of definition, with criteria differing between the ATP, WHO, and other definitions

Multiple different phenotypes included within the metabolic syndrome

Lack of a consistent evidence-base for setting the thresholds for the various components in the definitions

Kahn, R. Diabetes Care 2005; 28:2289.

Page 40: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

Inclusion of patients with clinical CVD or diabetes as part of the syndrome which is intended to define risk for these diseases Other risk factors for CVD which are not components of the metabolic syndrome, such as inflammatory markers, smoking and LDL, may have equal or greater bearing on risk.

A CRITICAL LOOK AT THE METABOLIC SYNDROME 

Kahn, R. Diabetes Care 2005; 28:2289.

Page 41: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

The CVD risk associated with the metabolic syndrome has not been shown to be greater than the sum of its individual components

The critical weakness of the current metabolic syndrome construct is that treatment of the syndrome is no different than treatment for each of its components.

1- Grundy, SM. Circulation 2005; 112:2735. 2- Sundstrom, J. Diabetes Care 2006; 29:1673.

A CRITICAL LOOK AT THE METABOLIC SYNDROME 

Page 42: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

All agree that the presence of one component of the metabolic syndrome should lead to evaluation for other risk factors. Whether patient benefit is gained from diagnosing patients with a syndrome of such uncertain characteristics or predictive value remains an open question.

Page 43: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

Treatment

lifestyle therapies as first-line management• weight reduction• increased physical activity

Secondary treatment of individual components

Page 44: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

Summary

20-25 % of the world adult population have the metabolic syndrome ( MTS) , and these are :Metabolic syndrome increases the risk of both CVD and diabetes mellitus. - twice likely to die - 3 times likely to have a heart attack or stroke - 5 times at risk to develop diabetes type 2

Page 45: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences

• Insulin resistance and obesity play primary roles.

• Many of the risk factors are modifiable.• Treatment should be initiated for each of

the components of metabolic syndrome to lower mortality and morbidity.

Summary

Page 46: Metabolic Syndrome Malek M., MD Associated Professor of Endocrinology and Metabolism Semnan University of Medical Sciences